Biorthex Anticipating Fourth-Quarter Roll-Out Of SpineCor Scoliosis Brace
This article was originally published in The Gray Sheet
Biorthex is planning a fourth-quarter U.S. launch of its SpineCor scoliosis brace, pending 510(k) clearance by FDA. Priced at approximately $1,000, the device will be positioned as an alternative and less restrictive treatment for early idiopathic scoliosis.
You may also be interested in...
Biorthex' recent IDE for the Actipore ACF places the Montreal-based firm with Medtronic and Synthes-Stratec in developing cervical implant approvals for the U.S. market
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.